Reality Check

MMIT Reality Check on Neutropenia (Feb 2021)

According to our recent payer coverage analysis for neutropenia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this new res...
0 Comments

MMIT Reality Check on Multiple Sclerosis (Jan 2021)

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this ...
0 Comments

MMIT Reality Check on Macular Edema (Jan 2021)

According to our recent payer coverage analysis for macular edema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this new r...
0 Comments

MMIT Reality Check on Epilepsy (Jan 2021)

According to our recent payer coverage analysis for epilepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this new resear...
0 Comments

MMIT Reality Check on Non-Small Cell Lung Cancer ALK+ or ROS1+ (Jan 2021)

According to our recent payer coverage analysis for non-small cell lung cancer ALK+ or ROS1+ treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To he...
0 Comments

MMIT Reality Check on Metastatic Prostate Cancer (Dec 2020)

According to our recent payer coverage analysis for metastatic prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense ...
0 Comments

MMIT Reality Check on Migraine Prevention (Dec 2020)

According to our recent payer coverage analysis for migraine prevention treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this...
0 Comments

MMIT Reality Check on Breast Cancer HR+/HER2+ (Dec 2020)

According to our recent payer coverage analysis for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer treatments, combined with news from key healthcare influence...
0 Comments

MMIT Reality Check on Nonmetastatic Prostate Cancer (Dec 2020)

According to our recent payer coverage analysis for nonmetastatic prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sen...
0 Comments

MMIT Reality Check on Ovarian Cancer (Dec 2020)

According to our recent payer coverage analysis for ovarian cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this new ...
0 Comments